The results of CardinALS showed utreloxastat failed to meet its main and secondary goals, including several disease-related ...
Citi raised the firm’s price target on PTC Therapeutics (PTCT) to $32 from $26 and keeps a Sell rating on the shares. The firm updated the company’s model to reflect the Novartis collaboration, which ...
PTC Therapeutics, Inc. (PTCT) stock saw a modest uptick, ending the day at $52.07 which represents a slight increase of $8.19 or 18.66% from the prior close of $43.88. The stock opened at $52.08 and ...
Novartis licensed PTC's PTC518 Huntington's disease program and related molecules and will pay $1 billion upfront as well as other costs.
PTC Therapeutics (PTCT – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Tazeen ...
Novartis has entered a worldwide licensing and partnership agreement with PTC Therapeutics to develop PTC518, a potential ...
PTC Therapeutics Inc. said a “highly competitive process with several parties involved” led to the deal centered on the ...
Novartis will partner with PTC Therapeutics to develop PTC’s PTC518 Huntington's disease program and an unspecified number of related molecules, through an up-to-$2.9 billion exclusive global license ...
A roundup of significant health updates globally includes Sanofi's major investment in China, New Zealand suspending poultry ...
Monday’s agreement comes days after PTC discontinued the development of another asset, utreloxastat, due to disappointing ...
The Swiss pharmaceutical company invests in a PTC Therapeutics program to develop treatment for Huntington’s disease.
Shares of PTC Therapeutics surged Monday when the pharmaceutical firm announced it struck a nearly $2 billion license and ...